Floatz logo

Orelabrutinib

High Grade B-Cell Lymphoma, Not Otherwise Specified

Shandong Provincial HospitalSmall moleculePhase 3Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
81/ 100

Competitive context

90 Active assets in the High Grade B-Cell Lymphoma, Not Otherwise Specified cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
University of Washington
Phase 3BB
Ifosfamide
University of California, Davis
Phase 3BB
VINCRISTINE SULFATE
National Cancer Institute (NCI)
Phase 2/3BB
PREDNISONE TABLETS
National Cancer Institute (NCI)
Phase 3BB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
National Cancer Institute (NCI)
Phase 3BB

View all 50 →

Same molecule, other indications

Orelabrutinib is also rated in:

marginal zone lymphomaDormant
BBB
Indicative ·
73 / 100
View asset →
primary central nervous system lymphomaDormant
BB
Indicative ·
70 / 100
View asset →
chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →